ClinicalTrials.gg
RecruitingNCT06186063AmyBoneUpdated Feb 21, 2024

The Role of Amylin in Bone Metabolism

An interventional study of Pramlintide and Placebo (saline) infusion in Bone Diseases, Metabolic and Type 1 Diabetes, sponsored by Filip Krag Knop. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-21.

Sponsored by Filip Krag Knop · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2024, 2 years 3 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 26 studies in Bone Diseases, Metabolic with a site in Denmark — 2 open to participants now, 5 under way, none of them phase 3. Bone Diseases, Metabolic · Denmark.

Planned enrollment
21st of 23
20 · median 85
Started
2024
with 2 others
No phase
9 of 26
1 open now
Registered
21st of 26
by date
Lead sponsor
1 of 26
Filip Krag Knop

Among the 26 studies in Bone Diseases, Metabolic with a site in Denmark, this one is the 21st largest by planned enrollment of the 23 interventional ones that give a count, is one of 3 that started in 2024, is one of 9 with no phase, and was the 21st registered.

Bone Diseases, Metabolic

663 studies on the registry are indexed under Bone Diseases, Metabolic; 95 are open to participants now.

Browse Bone Diseases, Metabolic studies →

Open to participants now

2 of the 26 studies in Bone Diseases, Metabolic with a site in Denmark are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Bone Diseases, Metabolic with a site in Denmark, or all of them as a file.
02

Study summary

The clinical study aims to investigate the effect of the intravenously administrated amylin analogue (pramlintide) on the circulating levels of C-terminal telopeptide of type I collagen (CTX-1) (a marker of bone resorption) and N-terminal propeptide of type I procollagen (P1NP) (a marker of bone formation) in individuals with type 1 diabetes and matched healthy controls during fasting euglycemic conditions.

Read the detailed description

Using a randomised double blinded placebo-controlled crossover design the investigators will evaluate the effects of the intravenously administrated amylin analogue (pramlintide) on circulating levels of CTX-1 and P1NP in ten individuals with type 1 diabetes and ten healthy controls matched for age, gender and body mass index (BMI) during fasting and euglycemic conditions. Each participant will receive double-blinded infusions of pramlintide (3 pmol/kg/min) and saline on two separate study days performed in randomised order.

The primary endpoints are the relative changes in the plasma levels of P1NP and CTX-1. The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma CTX-1 and P1NP as well as %-changes from baseline including nadir.

The secondary endpoints encompass changes in plasma concentrations of calcium, parathyroid hormone (PTH), alkaline phosphatase, osteocalcin, glucagon, insulin, C-peptide, glucose, glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 and glucagon-like peptide 2.

03

Conditions studied

  • Bone Diseases, Metabolic
  • Type 1 Diabetes
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion criteria type 1 diabetes:

  • Caucasian ethnicity
  • Age between 18 and 60 years
  • between 18.5 and 27 kg/m2
  • Type 1 diabetes (diagnosed according to the criteria of the World Health Organization) with \<69 mmol/mol (\<8.5%) and
  • Type 1 diabetes duration of 2-20 years
  • C-peptide negative (stimulated C-peptide ≤30 pmol/l)
  • Treatment with a stable basal-bolus or insulin pump regimen for ≥3 months
  • Normal vitamin D (>50 nmol/l)

Exclusion criteria type 1 diabetes:

  • Anaemia ( below normal range)
  • Liver disease (ALAT and/or ASAT >2 times normal values) or history of hepatobiliary disorder
  • Nephropathy ( \<60 ml/min/1,73m2 and/or microalbuminuria)
  • Microvascular complications except non-proliferative retinopathy
  • Treatment with anti-osteoporosis medication or
  • Fractures within the last 6 months
  • For women: currently perimenopausal or
  • Diseases affecting calcium metabolism (e.g. hypoparathyroidism, hyperparathyroidism, osteoporosis, vitamin D deficiency and cancer)
  • Pregnancy or breastfeeding
  • Any physical or psychological condition that the investigator feels would interfere with trial participation
  • Treatment with any glucose-lowering drugs beside insulin, treatment with medication against osteoporosis or treatment with any form of glucocorticoids

Inclusion criteria healthy controls:

  • Caucasian ethnicity
  • Age between 18 and 60 years
  • BMI between 18.5 and 27 kg/m2
  • Fasting plasma glucose ≤7.0 mmol/l and glycated haemoglobin (HbA1c) \<48 mmol/mol
  • Normal blood haemoglobin (8.3-10.5 mmol/l (males) and 7.3 - 9.5 mmol/l (females))
  • Normal plasma vitamin D (>50 nmol/l)
  • Informed consent

Exclusion criteria healthy controls:

  • Any form of diabetes (according to World Health Organization criteria)
  • Anaemia (haemoglobin below normal range)
  • Nephropathy (eGFR \<60 ml/min/1,73m2 and/or microalbuminuria)
  • Known liver disease and/or (ALAT) or aspartate transaminase (ASAT) >2 × upper normal limit
  • Any fractures within the last 6 months
  • For women: currently perimenopausal or postmenopausal
  • Diseases affecting calcium metabolism (e.g. hypoparathyroidism, hyperparathyroidism, osteoporosis, vitamin D deficiency and cancer)
  • Pregnancy or breastfeeding
  • Any condition considered incompatible with participation by the investigators
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Pramlintide infusion

    A stable amylin analogue.

    Other: Pramlintide

  • Placebo comparator
    Placebo infusion

    Isotonic saline (0.9% NaCl).

    Other: Placebo (saline) infusion

Interventions

  • OtherPramlintide

    At time 0 min, continuous infusion of a stable amylin analogue (pramlintide) will be initiated at a rate of 3.0 pmol/kg/min. The infusion will be terminated after 180 minutes.

  • OtherPlacebo (saline) infusion

    At time 0 min, continuous infusion of isotonic saline will be initiated at a rate of 150 ml/h. The infusion will be terminated after 180 minutes.

06

What researchers measure

Primary outcomes

  1. Relative changes in the plasma levels of C-terminal telopeptide of type I collagen (CTX-1)

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma CTX-1 as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

  2. Relative changes in the plasma levels of N-terminal propeptide of type I procollagen (P1NP)

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma P1NP as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

Secondary outcomes

  1. Changes in plasma concentrations of glucagon.

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

  2. Changes in plasma concentrations of insulin.

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

  3. Changes in plasma concentrations of C-peptide.

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

  4. Changes in plasma concentrations of glucose.

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

  5. Changes in plasma concentrations of glucose-dependent insulinotropic polypeptide (GIP).

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

  6. Changes in plasma concentrations of glucagon-like peptide 1 (GLP-1).

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

  7. Changes in plasma concentrations of glucagon-like peptide 2 (GLP-2).

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

  8. Changes in plasma concentrations of calcium.

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

  9. Changes in plasma concentrations of parathyroid hormone (PTH)

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

  10. Changes in plasma concentrations of alkaline phosphatase

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

  11. Changes in plasma concentrations of osteocalcin

    The changes in plasma concentrations will be assessed by the total and incremental (baseline-subtracted) area under the curve for plasma levels as well as %-changes from baseline including nadir.

    Time frame: From -15 minutes to 180 minutes

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Aug 2024, 5 months after the start.

Of 161 non-industry interventional studies with no phase under Bone Diseases, Metabolic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 38. This study's planned 5 months is below that.

Counting every sponsor, half of 177 studies reached it within 22 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2023
First posted
Dec 29, 2023
StartActual
Feb 12, 2024
Primary completionEst.
Aug 1, 2024
CompletionEst.
Aug 1, 2024
Last update
Feb 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06186063
Lead sponsor
Filip Krag Knop
Responsible party
Filip Krag Knop (Professor, MD, PhD, University Hospital, Gentofte, Copenhagen) — Sponsor-investigator
First posted
Dec 29, 2023
Start date
Feb 12, 2024
Primary completion
Aug 1, 2024 (estimated)
Completion
Aug 1, 2024 (estimated)
Last update
Feb 21, 2024

Study contacts

Mathilde K. Preskou, MD
Contact
emma.mathilde.kirsmeier.preskou.01@regionh.dk
+45 2349 6823
Filip K. Knop, Professor, MD, PhD
principal investigator · Center for Clinical Metabolic Research, Gentofte Hospital, Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion